in the assumptions. CONCLUSIONS: Compared with usual therapeutic strategies of anemia, the use of intravenous iron appears to be significantly cost saving in chemotherapy-induced anemia in breast cancers and gastrointestinal cancers. OBJECTIVES:The objective of this study was to determine, from the perspective of PMH, the financial impact of treating patients with CLL using R and intravenous FC (R-FC IV) versus R and orally administered FC (R-FC PO). METHODS: A cost analysis was performed from the perspective of PMH. All drug and administration costs were obtained from relevant sources in the province of Ontario and validated by PMH. Rituximab dosing was set at 375 mg/m 2 for cycle 1 (day 1) and 500 mg/m 2 of cycles 2-6 (day 1). Intravenous F and C were dosed at 25 mg/m 2 and 250 mg/m 2 , respectively, for 6 cycles (days 1-3). Oral dosing of these drugs was set at 40 mg/m 2 and 325 mg/m 2 , respectively. Drug utilization was estimated based on a body surface area of 1.8 m 2 .